Clinical Role - Hospital
Skidki-na-vse® is at the forefront of providing the latest clinical updates, patient counseling tools and innovative solutions to hospital pharmacists and reaches more than 200,000 pharmacy professionals in total.
A webinar held by Trellis Rx discussed actionable ways to establish a successful clinic-based specialty pharmacy approach.
NAMI Basics OnDemand is an adaptation of the in-person NAMI Basics, a free, 6-session education program for parents, caregivers, and other family who provide care for adolescents aged 22 years or younger who are experiencing mental health symptoms.
Skidki-na-vse Continuing Education™ Announces Keynote Speakers for Directions in Oncology Pharmacy™ Fall Conference Series
The keynote, Priming Pharmacists for Making an Impact in Oncology Value-Based Care, sets the stage for the entire conference and highlights how pharmacists are critical to the multidisciplinary team in providing value in patient-centered oncology care.
A new study by Prime Therapeutics LLC has shown a sharp increase in the number of drug "super spenders," defined by the researchers as members with pharmacy and medical drug therapy claims of $250,000 or more annually.
The FDA is continuing to test ranitidine products from multiple manufacturers following the discovery of impurities in low levels in some medicines, including Zantac.
The National Institute on Aging (NIA) has launched 2 new research centers, the Alzheimer Centers for the Discovery of New Medicines, designed to diversify and strengthen the Alzheimer disease drug development pipeline.
Oprah Winfrey’s message is clear: the flu and pneumonia vaccines are important.
Two lawsuits against the FDA have been resolved in a conclusion favorable to Endo International, which argued that vasporessin should be excluded from the agency’s compounding list.
Johnson & Johnson and its Janssen Pharmaceutical Cos unit have agreed to a more than $10 million settlement, rather than allowing the matter go to federal trial.
Fulvestrant injection treats certain types of breast cancer in post-menopausal women who were not previously treated with endocrine therapy and as a combination for advanced or metastatic breast cancer.
Ivosidenib improved progression-free survival with a promising trend toward improved overall survival in patients with IDH1-mutated cholangiocarcinoma.
Apalutamide (Erleada) showed an overall survival benefit in patients with non-metastatic castration-resistant prostate cancer.
+ Load More